Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

Video

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma (MCL).

The long-term efficacy with CAR T-cell therapy in MCL is not yet fully understood, says Skarbnik. Additionally, it is unknown whether sequencing CAR T-cell therapy before a BTK inhibitor affects response rate or duration of response in this patient population, Skarbnik says. Retrospective data could inform whether that sequencing strategy is feasible and efficacious, Skarbnik adds.

Currently, CAR T-cell therapy appears to have the most utility after frontline induction therapy in younger patients with MCL who experience early recurrence and have undergone transplant, Skarbnik says. Additionally, the modality is warranted in patients who recur after treatment with BTK inhibitors because few available agents are able to salvage these patients, Skarbnik says. In addition to CAR T-cell therapy, rituximab (Rituxan) plus bendamustine and low-dose cytarabine has demonstrated good response rates in patients with MCL who have relapsed on or are refractory to BTK inhibitors, concludes Skarbnik.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.